دورية أكاديمية
أعرض في EDS

Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.

التفاصيل البيبلوغرافية
العنوان: Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.
المؤلفون: Karim H; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Grawe F; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany., Völter F; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany., Auernhammer C; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany.; Department of Internal Medicine 4, University Hospital, LMU Munich, Munich, Germany., Rübenthaler J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany., Ricke J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany., Ingenerf M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Schmid-Tannwald C; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany.
المصدر: Radiology and oncology [Radiol Oncol] 2024 Jun 12; Vol. 58 (3), pp. 348-356. Date of Electronic Publication: 2024 Jun 12 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Sciendo Country of Publication: Poland NLM ID: 9317213 Publication Model: eCollection Cited Medium: Internet ISSN: 1581-3207 (Electronic) Linking ISSN: 13182099 NLM ISO Abbreviation: Radiol Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: [Warsaw, Poland] : Sciendo
Original Publication: Ljubljana : Slovenian Medical Society, Section of Radiology [and] Croatian Medical Association, Croatian Society of Radiology, [1992-
مواضيع طبية MeSH: Everolimus*/therapeutic use , Everolimus*/administration & dosage , Positron Emission Tomography Computed Tomography*/methods , Neuroendocrine Tumors*/drug therapy , Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/mortality , Liver Neoplasms*/drug therapy , Liver Neoplasms*/diagnostic imaging , Liver Neoplasms*/secondary, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Organometallic Compounds/therapeutic use ; Radiopharmaceuticals ; Antineoplastic Agents/therapeutic use ; Receptors, Somatostatin/metabolism ; Octreotide/analogs & derivatives ; Octreotide/therapeutic use ; Progression-Free Survival ; Treatment Outcome
مستخلص: Background: This study aimed to assess 68 Ga-DOTA-TATE (-TOC) PET/CT quantitative parameters in monitoring and predicting everolimus response in neuroendocrine tumor (NET) patients with hepatic metastases (NELM).
Patients and Methods: This retrospective analysis included 29 patients with 62 target lesions undergoing everolimus treatment and pre-therapy, and follow-up 68 Ga-DOTA-TATE (-TOC) PET/CT scans. Response evaluation utilized progression-free survival (PFS) categorized as responders (R; PFS > 6 months) and non-responders (NR; PFS ≤ 6 months). Lesion size and density, along with maximum and median standardize uptake value (SUV) in target lesions, liver, and spleen were assessed. Tumor-to-spleen (T/S) and tumor-to-liver (T/L) ratios were calculated, including the tumor-to-spleen (T/S) ratio and tumor-to-liver (T/L) ratio (using SUVmax/SUVmax, SUVmax/SUVmean, and SUVmean/SUVmean).
Results: PET/CT scans were acquired 19 days (interquartile range [IQR] 69 days) pre-treatment and 127 days (IQR 74 days) post-starting everolimus. The overall median PFS was 264 days (95% CI: 134-394 days). R exhibited significant decreases in Tmax/Lmax and Tmean/Lmax ratios compared to NR (p = 0.01). In univariate Cox regression, Tmean/Lmax ratio was the sole prognostic parameter associated with PFS (HR 0.5, 95% CI 0.28-0.92, p = 0.03). Percentage changes in T/L and T/S ratios were significant predictors of PFS, with the highest area under curve (AUC) for the percentage change of Tmean/Lmax (AUC = 0.73). An optimal threshold of < 2.5% identified patients with longer PFS (p = 0.003). No other imaging or clinical parameters were predictive of PFS.
Conclusions: This study highlights the potential of quantitative SSTR-PET/CT in predicting and monitoring everolimus response in NET patients. Liver metastasis-to-liver parenchyma ratios outperformed size-based criteria, and Tmean/Lmax ratio may serve as a prognostic marker for PFS, warranting larger cohort investigation.
(© 2024 Homeira Karim et al., published by Sciendo.)
References: Lancet. 2016 Mar 5;387(10022):968-977. (PMID: 26703889)
Clin Mol Hepatol. 2014 Jun;20(2):218-22. (PMID: 25032190)
EJNMMI Res. 2020 Jun 15;10(1):63. (PMID: 32542576)
Ann N Y Acad Sci. 2004 Apr;1014:13-27. (PMID: 15153416)
Mol Imaging Biol. 2015 Jun;17(3):313-8. (PMID: 25319765)
Diagn Interv Imaging. 2014 Mar;95(3):289-300. (PMID: 24034971)
Nucl Med Rev Cent East Eur. 2018;21(1):66-70. (PMID: 29319140)
Cancers (Basel). 2020 Nov 10;12(11):. (PMID: 33182575)
Cancers (Basel). 2021 Aug 27;13(17):. (PMID: 34503131)
Eur J Med Res. 2013 Jul 03;18:22. (PMID: 23822543)
Q J Nucl Med Mol Imaging. 2015 Mar;59(1):116-20. (PMID: 24382404)
Clin Nucl Med. 2018 Nov;43(11):802-810. (PMID: 30247209)
Virchows Arch. 2002 May;440(5):461-75. (PMID: 12021920)
Radiology. 2016 Aug;280(2):576-84. (PMID: 26909647)
JAMA Oncol. 2017 Oct 01;3(10):1335-1342. (PMID: 28448665)
Expert Opin Pharmacother. 2018 Jun;19(8):909-928. (PMID: 29757017)
Theranostics. 2014 Jan 29;4(4):336-65. (PMID: 24578720)
Cancers (Basel). 2019 Jun 14;11(6):. (PMID: 31207914)
Ann Diagn Pathol. 2017 Aug;29:11-16. (PMID: 28807335)
J Nucl Med. 2010 Sep;51(9):1349-56. (PMID: 20720050)
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907. (PMID: 23460395)
Clin Nucl Med. 2010 May;35(5):321-8. (PMID: 20395703)
Radiother Oncol. 2019 Dec;141:108-115. (PMID: 31542317)
Ann Oncol. 2020 Jul;31(7):844-860. (PMID: 32272208)
N Engl J Med. 2011 Feb 10;364(6):514-23. (PMID: 21306238)
Cancer Imaging. 2018 Jan 24;18(1):3. (PMID: 29361984)
J Clin Oncol. 2016 Nov 10;34(32):3906-3913. (PMID: 27621394)
J Nucl Med. 2016 Mar;57(3):355-60. (PMID: 26609176)
J Nucl Med. 2020 Feb;61(2):217-221. (PMID: 31302632)
Lancet Diabetes Endocrinol. 2018 May;6(5):404-415. (PMID: 29229497)
J Med Chem. 2001 Jun 7;44(12):2027-34. (PMID: 11384247)
Cancer. 2014 Mar 1;120(5):711-21. (PMID: 24264883)
Front Endocrinol (Lausanne). 2022 Aug 15;13:929391. (PMID: 36046793)
Cancers (Basel). 2023 Jul 12;15(14):. (PMID: 37509242)
Br J Cancer. 2019 Oct;121(7):537-544. (PMID: 31477779)
Cancer Metastasis Rev. 2015 Dec;34(4):823-42. (PMID: 26433592)
فهرسة مساهمة: Keywords: SSTR-PET/CT; everolimus; neuroendocrine tumors; response
المشرفين على المادة: 9HW64Q8G6G (Everolimus)
0 (Organometallic Compounds)
0 (Radiopharmaceuticals)
0 (Antineoplastic Agents)
0 (Receptors, Somatostatin)
RWM8CCW8GP (Octreotide)
9L17Y0H71P (gallium Ga 68 dotatate)
تواريخ الأحداث: Date Created: 20240611 Date Completed: 20240917 Latest Revision: 20240919
رمز التحديث: 20240919
مُعرف محوري في PubMed: PMC11406901
DOI: 10.2478/raon-2024-0032
PMID: 38861687
قاعدة البيانات: MEDLINE
الوصف
تدمد:1581-3207
DOI:10.2478/raon-2024-0032